BioSpace News Archive

Aphaia Pharma today announced the first patient has been dosed in a Phase 2 study evaluating the safety and efficacy of its lead candidate, APH-012, to improve glucose tolerance in patients with prediabetes.

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report first quarter 2023 financial results after the Nasdaq Global Market closes on Tuesday, May 2, 2023.

Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) (“Sirona”) is pleased to announce that the clinical trial results, for novel anti-aging compound TFC-1326, have exceeded even high expectations on key criteria.

Strata Oncology, Inc., a next-generation precision oncology company enabling smarter and earlier cancer treatment, announced the launch of Strata Select™, a first-of-its-kind molecular profiling test for patients with advanced cancer.

ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA, or “ZyVersa”), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatment of inflammatory and renal diseases, announces publication of an article in the peer-reviewed Journal of Neuroinflammation supporting the potential of ASC specks as a therapeutic target for Parkinson’s disease.

Life Science Washington, the state’s industry trade association, today released a new Economic Impact Report, revealing Washington state’s $35.3 billion life science industry supports more than 100,000 jobs throughout the state and continues to serve as a buffer during economic downturns.

Perrigo Company plc (NYSE: PRGO), a leading provider of Consumer Self-Care Products, today announced that it plans to issue its first quarter 2023 results on Tuesday, May 9, 2023.

The Celiac Disease Foundation, a world leader in patient advocacy, and Takeda Development Center Americas, a global biopharmaceutical leader, are proud to announce the Celiac Disease Foundation–Takeda Early Career Research Award; an award designed to attract promising researchers to the study of celiac disease.

SPR® Therapeutics announced the introduction of the SPRINT extensa XT System with bimodal peripheral nerve stimulation (PNS), designed to deliver a comprehensive approach to the alleviation of pain by treating dual nerve targets with synergistic stimulation modalities.

Khiron Life Sciences Corp. (TSXV: KHRN) (OTCQB: KHRNF) (FSE: A2JMZC) (“Khiron” or the “Company”), welcomes the clear affirmation of the Federal Joint Committee (G-BA) regarding the future of medical cannabis in Germany as a treatment option reimbursed by statutory health insurance (SHI).